A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Abstract Background CD19 chimeric antigen receptor (CAR) therapy has achieved impressive success in relapsed or refractory (R/R) B-cell malignancies, but relapse due to antigen escape is increasingly appearing reported. As the expression profile of CD22 is similar to that of CD19, CD22 has become a...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Yu Zhang, Saisai Li, Ying Wang, Yang Lu, Yingxi Xu, Qing Rao, Huijun Wang, Haiyan Xing, Zheng Tian, Kejing Tang, Lulu Lv, Min Wang, Jianxiang Wang
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2022-03-01
سلاسل:	Experimental Hematology & Oncology
الموضوعات:	CD22 HIB22 CD19 CAR-T Sequential therapy B-ALL
الوصول للمادة أونلاين:	https://doi.org/10.1186/s40164-022-00270-5
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!